List of SBIR/STTR awards granted to Reveal Pharmaceuticals
Reveal PharmaceuticalsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Reveal Pharmaceuticals in December, 2020 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HL156713-01 | Phase I | 300,000 | December 15, 2020 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in September, 2021 for $1,149,940.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44CA268392-01 | Phase II | 1,149,940 | September 24, 2021 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in August, 2020 for $996,175.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44CA239935-02 | Phase II | 996,175 | August 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Reveal Pharmaceuticals in August, 2019 for $299,811.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44CA239935-01A1 | Phase I | 299,811 | August 8, 2019 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in May, 2018 for $1,534,007.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44DK113906-02 | Phase II | 1,534,007 | May 1, 2018 | |||||||
A SBIR Phase I contract was awarded to Reveal Pharmaceuticals in September, 2022 for $290,410.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44DK134295-01 | Phase I | 290,410 | September 15, 2022 | |||||||
A SBIR Phase I contract was awarded to Reveal Pharmaceuticals in May, 2017 for $210,384.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44DK113906-01 | Phase I | 210,384 | May 11, 2017 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in June, 2023 for $1,026,595.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44HL156713-02 | Phase II | 1,026,595 | June 1, 2023 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in September, 2023 for $980,165.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44DK134295-02 | Phase II | 980,165 | September 1, 2023 | |||||||
A SBIR Phase II contract was awarded to Reveal Pharmaceuticals in June, 2023 for $2,025,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 9R44CA261240-04A1 | Phase II | 2,025,000 | June 5, 2023 |
